Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Swings and roundabouts of VBP

This article was originally published in Scrip

Executive Summary

It looks as though drugs that get patients back to work quicker and those that tackle diseases affecting younger patients' quality of life could be winners under the UK's value-based pricing system. With just three months until VBP is supposed to be up and running, details have so far been elusive, but options of how the scheme may work are now being laid on the table.

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC022999

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel